Skip to content
    COR
    Earnings call· Sep 2025(Q4 FY25)

    Cencora, Inc. COR

    Nov 5, 2025 Source

    Executive summary

    Cencora Q4 FY25 — Strong Specialty Performance Drives Raised Long-Term Guidance

    Cencora delivered robust Q4 FY25 results, driven by strong performance in its U.S. Healthcare Solutions segment and strategic focus on specialty. The company raised its long-term adjusted operating income and EPS growth guidance, reflecting confidence in its market positioning and MSO platform strategy. A strategic portfolio review led to the creation of an "other" segment for businesses under evaluation, aiming to sharpen focus on core growth areas.

    Highlights

    5

    • Adjusted operating income and adjusted diluted EPS grew 16% in FY25.

    • Q4 adjusted diluted EPS increased 15% to $3.84.

    • Long-term adjusted operating income growth guidance raised to 6%-9% and adjusted EPS growth to 9%-13%.

    • Consolidated gross profit increased 18% to $2.9 billion in Q4.

    • Annual dividend increased by 9%, marking the 21st consecutive annual increase.

    Concerns

    4

    • Goodwill impairment of $724 million related to PharmaLex in Q4.

    • Net interest expense increased by $57 million to $78 million in Q4 due to RCA acquisition debt.

    • Loss of an oncology customer at the end of June will create a net headwind of 1% for U.S. Healthcare Solutions segment in Q1-Q3 FY26.

    • International Healthcare Solutions segment operating income decreased 2% (6% constant currency) in Q4 due to consulting services pressure.

    Guidance & targets

    18
    CategoryTargetConfidence
    Long-term Adjusted Operating Income Growth
    6% to 9%
    high materiality
    High
    Long-term Adjusted EPS Growth
    9% to 13%
    high materiality
    High
    Adjusted Diluted EPS
    $17.45 to $17.75
    high materiality
    High
    Consolidated Revenue Growth
    5% to 7%
    medium materiality
    High
    U.S. Healthcare Solutions Revenue Growth
    5% to 7%
    medium materiality
    High
    International Healthcare Solutions Revenue Growth
    6% to 8%
    medium materiality
    High
    Other Revenue Growth
    0% to 4%
    medium materiality
    High
    Consolidated Operating Income Growth
    8% to 10%
    high materiality
    High
    U.S. Healthcare Solutions Operating Income Growth
    9% to 11%
    high materiality
    High
    International Healthcare Solutions Operating Income Growth
    5% to 8%
    medium materiality
    High
    Other Operating Income Decline
    1% to 4%
    medium materiality
    High
    Interest Expense
    $315 million to $335 million
    medium materiality
    High
    Effective Tax Rate
    20% to 21%
    medium materiality
    High
    Full-year Average Share Count
    approximately 194 million shares
    medium materiality
    High
    Capital Expenditures
    approximately $900 million
    medium materiality
    High
    Adjusted Free Cash Flow
    approximately $3 billion
    high materiality
    High
    Long-term U.S. Healthcare Solutions Operating Income Growth
    6% to 9%
    high materiality
    High
    Long-term EPS Contribution from M&A and Share Repurchase
    3% to 4%
    medium materiality
    High

    Segment performance

    3
    SegmentRevenueYoYQoQMargin
    U.S. Healthcare Solutions
    Benefited from strong utilization trends and contribution from RCA. Strong volumes in specialty across health systems and physician practices.
    GLP-1 contribution to segment revenue growth: 50 bpsSpecialty volume growth: goodOncology customer loss impact: more than offset by partnerships
    		$75.8 billionapproximately 6%—$872 million
    International Healthcare Solutions
    Growth primarily from European distribution business. Operating income decrease due to pressure in global consulting services, partially offset by growth in other units. Strong demand for 3PL services in Europe.
    European distribution revenue growth: primary driverGlobal consulting services pressure: continuedGlobal specialty logistics shipment volumes: returned to growth
    		$7.9 billion8% (6% constant currency)—$151 million
    Other
    Includes MWI Animal Health, equity stake in Profarma, legacy U.S. Consulting hub services, and components of PharmaLex. Businesses are under strategic review.
    MWI Animal Health revenue contribution: nearly 70% of 'other's' revenue (FY25)MWI Animal Health FY25 revenue growth: 6%Profarma revenue contribution: about 1/4 of 'other's' revenue (FY25)
    		————

    Operational metrics

    18
    Adjusted Operating Income Growth
    16%YoY
    FY25

    Driven by strategic positioning in Specialty, thoughtful investments, and strong pharmaceutical utilization trends.

    Adjusted Diluted EPS Growth
    16%YoY
    FY25

    Driven by strategic positioning in Specialty, thoughtful investments, and strong pharmaceutical utilization trends.

    GLP-1 Contribution to Consolidated Revenue Growth
    40
    Q4 FY25

    Less meaningful contributor than in recent quarters.

    Consolidated Gross Profit
    $2.9 billionup 18%
    Q4 FY25

    Largely driven by gross profit growth in U.S. Healthcare Solutions segment.

    Consolidated Gross Profit Margin
    3.47%increase of 37 bps
    Q4 FY25

    Primarily due to gross profit contribution from RCA acquisition.

    Consolidated Operating Expenses
    $1.9 billionup 18%
    Q4 FY25

    Primarily due to RCA acquisition and overall revenue growth support.

    Net Interest Expense
    $78 millionincrease of $57 million
    Q4 FY25

    Primarily due to $3.3 billion debt raised for RCA acquisition.

    Effective Tax Rate
    20.6%compared to 20.3% in the prior year
    Q4 FY25

    null

    Diluted Share Count
    195.3 million1% decrease YoY
    Q4 FY25

    Primarily driven by opportunistic share repurchases.

    GLP-1 Sales Increase
    $876 million10% year over year
    Q4 FY25

    Represented a 50 basis point contribution to segment revenue growth.

    Goodwill Impairment
    $724 million
    Q4 FY25

    Related to PharmaLex due to persistent demand challenges and underperformance.

    Consolidated Revenue
    $321.3 billionup 9%
    FY25

    Driven by U.S. Healthcare Solutions segment growth of 10% and International Healthcare Solutions segment growth of 6%.

    Cash Balance
    $4.4 billion
    FY25 end

    null

    Capital Returned to Shareholders
    ~$900 million
    FY25

    Through dividends and share repurchases.

    Annual Dividend Increase
    9%
    Annual

    21st consecutive annual increase, aligning with low end of long-term adjusted diluted EPS growth guidance.

    Term Loan Repayment
    $500 million$700 million of $1.5 billion three-year term loan repaid to date
    Q4 FY25

    Part of the RCA financing.

    Supply Chain Infrastructure Investments
    $1 billion
    through 2030

    To support customers' continued growth and innovation, particularly in specialty.

    U.S. Healthcare Solutions Segment Net Headwind
    1%
    FY26

    Due to the loss of an oncology customer and incremental quarter of contribution from RCA.

    Industry KPIs

    4
    MetricValueDetails
    Utilization trendsstrong
    Pharmacy scripts specialty$876 millionUSD
    Segment revenue operating income5% to 7%%
    Adjusted EPS EBITDA leverage guidance$17.45 to $17.75USD

    Deals & partnerships

    3
    Retina Consultants of AmericaStrengthens leadership in specialty, MSO platform.

    Platform provides unique value for physicians, driving growth and contributing to patient outcomes.

    OneOncologyEquity investment with pathway to full ownership, MSO platform in oncology.

    Currently owned 35% by Cencora, 65% by private equity firm and physicians. Put-call structure in place for full ownership.

    [unnamed oncology customer]Customer acquired by a peer, leading to contract termination.

    Impact more than offset by partnerships in Q4 FY25.

    Risks & headwinds

    4
    PharmaLex Demand Challenges & ImpairmentQ4 FY25 (impairment), ongoing (demand challenges)

    $724 million goodwill impairment in Q4 FY25.

    Mitigation: Strategic review, decision to simplify PharmaLex's business to focus on pharmacovigilance, market access, and regulatory affairs; evaluating strategic alternatives for other service verticals.

    Oncology Customer LossQ1-Q3 FY26

    Net headwind of 1% for U.S. Healthcare Solutions segment in FY26 (for the first 3 quarters).

    Mitigation: Strong performance in other partnerships and contribution from RCA more than offset the impact in Q4 FY25; growth expected to pick up in Q4 FY26 as the company laps the loss.

    International Consulting Services PressureQ4 FY25, ongoing

    Contributed to a 2% decrease (6% constant currency) in International Healthcare Solutions segment operating income in Q4 FY25.

    Mitigation: Partially offset by growth in other business units in the segment; more tailored portfolio moving some PharmaLex assets to "other" and easier comparisons in FY26.

    Higher Interest ExpenseQ4 FY25, FY26

    Net interest expense increased $57 million to $78 million in Q4 FY25; expected interest expense of $315 million to $335 million for FY26.

    Mitigation: Repaid $500 million of existing term loan in Q4 FY25, totaling $700 million of the $1.5 billion term loan.

    What to watch in Q1 FY26

    5

    U.S. Healthcare Solutions Operating Income Growth

    Q1-Q3 FY26 (headwind), Q4 FY26 (pick up)
    Current25% (Q4 FY25 reported), 13% ex-RCA
    TargetGrowth picking up in Q4 FY26

    Why it matters

    To assess the impact of the oncology customer loss and the underlying organic growth trajectory of the core U.S. business.

    However, we will have a headwind related to this loss for the first 3 quarters of fiscal 2026. As you update your quarterly models to reflect the fiscal 2026 guidance, we would expect growth to pick up in the fourth quarter of our fiscal year as we begin to lap this customer loss.

    Q&A highlights

    6

    How do Cencora's strategic priorities evolve with the new "other" segment, and what are the plans for incremental MSO acquisitions, particularly given the focus on specialty?

    Bob Mauch emphasized a disciplined and focused strategic execution, dedicating resources to areas that differentiate Cencora, especially specialty and MSO platforms like RCA and OneOncology. He stated that the "other" businesses are not troubled but don't align with the sharpened focus. Jim Cleary added that RCA's strong performance and OneOncology's inorganic growth reinforce the MSO strategy, positively contributing to distribution and GPO business.

    “We are just being disciplined and focused in making sure that we can focus on where we have been really clear about where we are going to continue to differentiate ourselves.”

    asked by Lisa Gill · answered by Robert Mauch

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Portfolio Review and "Other" Segment

    Cencora undertook a thorough review of its portfolio, leading to the identification of businesses that do not align as closely with its pharmaceutical-centric strategy. These businesses, including MWI Animal Health, legacy U.S. hub services, equity investment in Profarma, and certain components of PharmaLex, are now grouped as "other" for financial reporting and are under evaluation for strategic alternatives. This move aims to sharpen focus and deploy resources more effectively on core growth priorities.

    02

    Focus on Specialty and MSO Platforms

    The company is strengthening its leadership in specialty, exemplified by the acquisition of Retina Consultants of America (RCA) and the pathway to full ownership of OneOncology. These MSO platforms are seen as key drivers for growth, enhancing patient access to innovative treatments, improving physician efficiency, and leveraging clinical trial expertise across retina and oncology. RCA's performance has exceeded expectations, particularly in clinical trial sites.

    03

    Significant Infrastructure Investments

    Cencora announced $1 billion in investments through 2030 to amplify its distribution network. This includes opening a second National Distribution Center and expanding existing specialty distribution capacity, particularly for cold chain storage. These investments are designed to support rising demand and complexity in the pharmaceutical supply chain and enhance resiliency and efficiency.

    04

    PharmaLex Restructuring and Impairment

    A $724 million goodwill impairment related to PharmaLex was recorded in Q4 FY25 due to persistent demand challenges and underperformance. As part of the strategic review, PharmaLex will now focus only on pharmacovigilance, market access, and regulatory affairs, with strategic alternatives being evaluated for its other service verticals.

    05

    Capital Allocation Strategy

    Cencora's capital deployment strategy prioritizes internal investments in infrastructure and technology, strategic M&A (like RCA and future OneOncology ownership), opportunistic share repurchases (targeting $1 billion in FY26), and maintaining a growing dividend (9% increase announced). The company aims for a more focused portfolio to drive better long-term returns.

    06

    Impact of Oncology Customer Loss

    The loss of an oncology customer (FCS) due to acquisition by a peer at the end of June FY25 created a headwind. This impact was fully reflected in Q4 FY25 results but will continue to be a net headwind for the U.S. Healthcare Solutions segment in the first three quarters of FY26, with growth expected to pick up in Q4 FY26 as the company laps this event.

    AI-generated summary of the company’s earnings call. Not investment advice.